THE IMPORTANCE OF ANTHROPOMETRIC PAREMETERS IN PATIENTS WITH SUBCLINICAL HYPOTHYROIDISM

Mersiha Mulic, Suada Muminovic, Fadil Skrijelj, Mersudin Mulic, Snezana Vujosevic

Abstract


Introduction: The concept of subclinical thyroid disease appeared in the 1980s when sensitive procedures for the measurement of the thyroid-stimulating hormone in the serum were introduced. Subclinical hypothyroidism is defined by the finding of elevated serum TSH concentrations with normal thyroid hormone levels. The incidence of subclinical hypothyroidism with increased cardiovascular risk has not yet been fully clarified.

The aim of the study was to identify anthropometric parameters that may indicate an increased cardiometabolic risk in patients with subclinical hypothyroidism.

Method: The study will include 140 patients aged 18-65, with 105 patients with subclinical hypothyroidism and a control group of 35 healthy, normally nourished subjects without subclinical hypothyroidism. A program of research will be carried out in all patients and it will include: detailed anamnesis and physical examination, anthropometric measurements (weight measurements, body height, waist circumference, hip circumference, body weight mass measurement by the bioelectrical impedance analysis method (%BFP), calculation of: body mass index (BMI), waist-to-hip circumference ratio (WC/HC), waist-to-height ratio (WC/Ht) and laboratory testing (FT3, FT4, TSH).

Results: Examinees with subclinical hypothyroidism had statistically significantly elevated mean TSH values (6.87+1.34 mIU/ml) compared to TSH euthyroid examinees (1.9+.88 mIU/ml). The mean age of subjects with subclinical hypothyroidism was 44.1511.23 years (MA = 43 years), and in subjects without subclinical hypothyroidism, 33.8010.60 years (MA = 33 years). In relation to the control group (euthyroid patients), patients with subclinical form of hypothyroidism had higher average mean values and statistically significantly higher incidence of elevated values: BMI (T test=7.465, p<0.0001; c2=35.977, p<0.0001), %BFP (T test=8.594, p<0.0001; c2=44.956, p<0.0001), WC (T test=6.262, p<0.0001; c2=48.865,p<0.0001), and WC/Ht ratio (T test=7.372, p<0.0001; c2=39.175, p<0.0001). The WC/HC ratio in the group with subclinical hypothyroidism was higher than in the group without subclinical hypothyroidism, but not statistically significant (T test=-0.946, p= ns; c2=0.622, p=0).

Conclusion: In the subclinical form of hypothyroidism, changes in the degree of nutrition and body weight can already be recorded, which, among other things, contributes to the development of increased cardiometabolic risk.


Keywords


subclinical hypothyroidism, anthropometric parameters, cardiometaolic risk

Full Text:

PDF

References


Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado Thyroid Disease prevalence study. Arch Intern Med. 2000; 160(4): 526–34.

Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT.Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab. 2005;90(1):581-5; discussion 586-7.

Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012;379(9821):1142-54.

Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008; 29(1):76–131.

Duggal J, Singh S, Barsano CP, Arora R. Cardiovascular risk with subclinical hy?erthyroidism and hypothyroidism: pathophysiology and management. Cardiometab Syndr. 2007; 2(3): 198-206.

Razvi S, Shakoor A, Vanderpump M, Weaver JU, Pearce SH. The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: a metaanalysis. J Clin Endocrinol Metab. 2008; 93(8): 2998-3007.

Neves C, Alves M, Medina JL, Delgado JL. Thyroid diseases, dyslipidemia and cardiovascular pathology. Rev Port Cardiol. 2008; 27(10): 1211-36.

Razvi S, Weaver JU, Vanderpump MP, Pearce SH. The incidence of ischemic heart disease and mortality in people with subclinical. Subclinical hypothyroidism: reanalysis of the Whickham Survey cohort. J Clin Endocrinol Metab. 2010; 95(4): 1734-40.

Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality.Thyroid Studies Collaboration. JAMA. 2010; 304(12): 1365-74.

McQuade C, Skugor M., Brennan DM, Hoar B, Stevenson C, Hoogwerf BJ. Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: a PreCIS database study. Thyroid. 2011; 21(8): 837–43.

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120(16): 1640–5.

Framingham Study Risk Score Profiles. Framingham Heart Study. www.framinghamheartstudy.org/risk/index.html. Accessed December 5, 2012.

Cooper DS. Clinikal practice.subclinical hipothyroidism. N Engl J Med. 2001; 345(4): 260-5.

Meier C, Staub JJ, Roth CB. Guglielmetti M, Kunz M, Miserez AR et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double-blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab. 2001; 86(10): 4860–6.

Kong WM, Sheikh MH, Lumb PJ, Naoumova RP, Freedman DB,Crook M, et al. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. Am J Med. 2002; 112(5):348–54.

Adrees M, Gibney J, El-Saeity N, Boran G. Effects of 18 months of L-T4 replacement in women with subclinical hypothyroidism. Clin Endocrinol (Oxf). 2009; 71(2):298–303.

Lioudaki E, Mavroeidi NG, Mikhailidis DP, Ganotakis ES. Subclinical hypothyroidism and vascular risk: an update. Hormones. 2013; 12(4): 495-506.

Madathil A, Hollingsworth KG, Blamire AM, Razvi S, Newton JL, Taylor R, et al. Levothyroxine improves abnormal cardiac bioenergetics in subclinical hypothyroidism: a cardiac magnetic resonance spectroscopic study. J Clin Endocrinol Metab. 2015; 100(4):E607–10.

Javed Z, Sathyapalan T. Levothyroxine treatment of mild subclinical hypothyroidism: a review of potential risks and benefits. Ther Adv. Endocrinol Metab. 2016; 7(1):12-23.

Muli? M, Halo O, Škrijelj F, Muli? B. Beneficial effects of levothyroxine in the treatment of subclinical hypothyroidism. Sanamed. 2016;11(3): 203–9.

Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA et al. Serum TSH, T4, and thyroid antibodies in the Unated States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002; 87(2): 489–99.

Karmisholt J, Andersen S, Laurberg PA. Variation in thyroid function in subclinical hypothyroidism: importance of clinical follow-up and therapy. Eur J Endocrinol. 2011;164(3):317-23.

Bianchi GP, Zaccheroni V, Solaroli E, Vescini F, Cerutti R, Zoli M, et al. Health-related quality of life in patients with thyroid disorders. Qual Life Res. 2004; 13(1):45–54.

Grabe HJ, Volzke H, Ludemann J, Wolff B, Schwahn C, John U, et al. Mental and physical complaints in thyroid disorders in the general population. Acta Psychiatr Scand. 2005; 112(4):286–293.

Sait Gonen M, Kisakol G, Savas Cilli A, Dikbas O, Gungor K, Inal A, et al. Assessment of anxiety in subclinical thyroid disorders. Endocr J. 2004; 51(3):311–15.

Taylor PN, Razvi S, Pearce SH, Dayan CM. Clinical review: a review of the clinical consequences of variation in thyroid function within the reference range. J Clin Endocrinol Metab. 2013; 98(9):3562–71.

Yang L, Lv X, Yue F, Wei D, Liu W, Zhang T. Subclinical hypothyroidism and the risk of metabolic syndrome: a meta-analysis of observational studies. Endocr research. 2016; 41 (2) : 158-65.

Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifi able risk factors associated with myocardial infarction in 52 countries (The INTERHEART study): case-controle study. Lancet. 2004; 364(9438):937–52.

Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome a new worldwide definition. Lancet. 2005;366(9491):1059-62.

The IDF consensus worldwide definition of the metabolic syndrome. Avaible from http://www.idf.org

Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity adults: the evidence report (published correction appears in Obes Res.1988;6:464). National Institutes of Health. Obes Res. 1988;6(suppl 2):51S-209S.

Ashwell, M, Gibson, S. Waist to height ratio as an indicator of 'early health risk': simpler and more predictive than using a 'matrix' based on BMI and waist circumference. BMJ Open.2016; 6(3):e010159.

Gibson S, Ashwell M. Non-overweight 'apples' have higher cardiometabolic risk factors than overweight 'pears': waist-to-height ratio is a better screening tool than BMI for blood levels of cholesterol and glycated haemoglobin. Obesity Facts. 2016. 8 (Suppl 1):139.

Ashwell M, Gibson S. A proposal for a primary screening tool: 'Keep your waist circumference to less than half your height'. BMC Med. 2014; 12(1): 207.

Ashwell M, Mayhwe, Richardson J, Rickayzen B. Waist-to-height ratio is more predictive of years of life lost than body mass index. PloS one. 2014;9(9):e103483.

Ashwell M, Gunn P, Gibson S: Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes Rev. 2012;13(3):275-86.

Ashwell M. Plea for simplicity: use of waist-to-height ratio as a primary screening tool to assess cardiometabolic risk Clin Obes. 2012;2(1-2):3-5.

World Health Organization. Obesity: preventing and maniging the global epidemic. Report of WHO consultation. WHO Tech Rep Ser. 2000;894:1-253.

Dietlein M, Kahaly G, Kobe C, Schmidt M, Derwahl KM, Schicha H. [Obesity, energy regulation and thyroid function: is borderline elevated TSH-level the cause or secondary phenomenon of obesity] [Article in German] Nuklearmedizin. 2008;47(5):181-7.

Grundy SM, Adams-Huet B, Vega GL. Variable contributions of fat content and distribution to metabolic syndrome risk factors. Metab Syndr Relat Disord. 2008;6(4):281-8.

Ginter E, Simko V. Adult obesity at the beginning of the 21st century: epidemiology, pathophysiology and health risk. Bratisl Lek Listy. 2008;109(5):224-30.

Cruz M, Weigensberg MJ, Huang TT, Ball G, Shaibi GQ, Goran MI. The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity. J Clin Endocrinol Metab. 2004;89(1):108–13.

Després JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol.2008;28(6):1039-49.

Veigas MN, Dharmalingam M., Marcus R.Sh. Oxidative stress in obesity and metabolic syndrome in Indians. Journal of Medical Biochemistry.2011; 30 (2): 115-20.




DOI: http://dx.doi.org/10.24125/sanamed.v13i1.200

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Mersiha Mulic, Suada Muminovic, Fadil Skrijelj, Mersudin Mulic

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.